Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients
暂无分享,去创建一个
A. Lazzarin | E. Sagnelli | C. Sagnelli | D. Barbanotti | F. Punzo | F. Rossi | H. Hasson | G. Bellini | N. Coppola | M. Merli | C. Minichini | S. Salpietro | E. Messina | C. Uberti-Foppa
[1] E. Sagnelli,et al. CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[2] A. Lazzarin,et al. TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype , 2016, World journal of gastroenterology.
[3] A. Lazzarin,et al. Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[4] E. Sagnelli,et al. Liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: Diagnostic methods and clinical impact. , 2015, World journal of hepatology.
[5] E. Sagnelli,et al. Role of genetic polymorphisms in hepatitis C virus chronic infection. , 2015, World journal of clinical cases.
[6] Q. Tong,et al. The endocannabinoid system and its therapeutic implications in rheumatoid arthritis. , 2015, International immunopharmacology.
[7] G. Cabral,et al. Cannabinoid inhibits HIV-1 Tat-stimulated adhesion of human monocyte-like cells to extracellular matrix proteins. , 2014, Life sciences.
[8] R. Brown, Jr.,et al. Review article: the endocannabinoid system in liver disease, a potential therapeutic target , 2014, Alimentary pharmacology & therapeutics.
[9] A. Localio,et al. Hepatic Decompensation in Antiretroviral-Treated Patients Co-Infected With HIV and Hepatitis C Virus Compared With Hepatitis C VirusMonoinfected Patients , 2014, Annals of Internal Medicine.
[10] E. Sagnelli,et al. Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[11] E. Sagnelli,et al. Cannabinoid Receptor 2-63 QQ Variant Is Associated with Persistently Normal Aminotransferase Serum Levels in Chronic Hepatitis C , 2014, PloS one.
[12] A. Lazzarin,et al. Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients , 2013, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.
[13] A. Lazzarin,et al. Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection , 2013, Infection.
[14] Y. Persidsky,et al. Cannabinoid Receptor 2: Potential Role in Immunomodulation and Neuroinflammation , 2013, Journal of Neuroimmune Pharmacology.
[15] A. Fasano,et al. The cannabinoid receptor type 2 Q63R variant increases the risk of celiac disease: implication for a novel molecular biomarker and future therapeutic intervention. , 2012, Pharmacological research.
[16] Lakshmi A. Devi,et al. Cannabinoid Receptor 2-Mediated Attenuation of CXCR4-Tropic HIV Infection in Primary CD4+ T Cells , 2012, PloS one.
[17] S. Perrotta,et al. CNR2 functional variant (Q63R) influences childhood immune thrombocytopenic purpura , 2011, Haematologica.
[18] A. Mallat,et al. Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice , 2011, Hepatology.
[19] W. Mcfarland,et al. Hepatitis C prevalence among HIV-positive MSM in San Francisco: 2004 and 2008. , 2011, Sexually transmitted diseases.
[20] P. Selwyn,et al. Comorbidity-Related Treatment Outcomes among HIV-Infected Adults in the Bronx, NY , 2011, Journal of Urban Health.
[21] A. Lazzarin,et al. Liver histology in HIV/hepatitis C-coinfected and HCV-monoinfected patients with persistently normal alanine aminotransferases. , 2010, Journal of acquired immune deficiency syndromes.
[22] W. M. Williams,et al. Functional consequences of nonsynonymous single nucleotide polymorphisms in the CB2 cannabinoid receptor , 2010, Pharmacogenetics and genomics.
[23] G. Bernardi,et al. Anandamide Suppresses Proliferation and Cytokine Release from Primary Human T-Lymphocytes Mainly via CB2 Receptors , 2010, PloS one.
[24] Mardge H. Cohen,et al. Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). , 2009, AIDS patient care and STDs.
[25] David B. Goldstein,et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.
[26] Dongyang Yu,et al. The HIV Envelope but Not VSV Glycoprotein Is Capable of Mediating HIV Latent Infection of Resting CD4 T Cells , 2009, PLoS pathogens.
[27] Jacques Fellay,et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.
[28] M. Andreoni,et al. Predictability of sustained virological response to pegylated interferon alpha-2b Plus ribavirin therapy by week-8 viral response in HIV-positive patients with chronic hepatitis C virus infection. , 2009, Current HIV research.
[29] E. Sagnelli,et al. HBV superinfection in HCV chronic carriers: A disease that is frequently severe but associated with the eradication of HCV , 2009, Hepatology.
[30] G. Cabral,et al. Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. , 2008, Endocrine, metabolic & immune disorders drug targets.
[31] F. Mach,et al. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. , 2008, American Journal of Physiology. Heart and Circulatory Physiology.
[32] N. Stella,et al. CB2 receptor‐mediated migration of immune cells: it can go either way , 2008, British journal of pharmacology.
[33] J. Rodríguez-Baño,et al. Clinical progression of hepatitis C virus–related chronic liver disease in human immunodeficiency virus–infected patients undergoing highly active antiretroviral therapy , 2007, Hepatology.
[34] Todd M. Allen,et al. Impaired Hepatitis C Virus-Specific T Cell Responses and Recurrent Hepatitis C Virus in HIV Coinfection , 2006, PLoS medicine.
[35] R. Ganju,et al. Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. , 2006, Molecular immunology.
[36] A. Lazzarin,et al. Liver Fibrosis in HIV-Positive Patients With Hepatitis C Virus: Role of Persistently Normal Alanine Aminotransferase Levels , 2006, Journal of acquired immune deficiency syndromes.
[37] A. Gerber,et al. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders , 2005, Journal of leukocyte biology.
[38] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[39] G. Lüchters,et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection , 2003, The Lancet.
[40] R. Chung,et al. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] T. Heeren,et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[42] C. Katlama,et al. Factors affecting liver fibrosis in human immunodeficiency virus–and hepatitis C virus–coinfected patients: Impact of protease inhibitor therapy , 2001, Hepatology.
[43] M. Gambardella,et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity , 2001, Hepatology.
[44] C. Katlama,et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients , 1999, Hepatology.
[45] T. Layden,et al. Impact of alcohol on the histological and clinical progression of Hepatitis C infection , 1998, Hepatology.
[46] P. Bedossa,et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.
[47] K. Ishak,et al. Histological grading and staging of chronic hepatitis. , 1995 .
[48] M A Gerber,et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. , 1992, The New England journal of medicine.
[49] C. Rui. Genetic variation in IL-28B and spontaneous clearance of hepatitis C virus , 2012 .
[50] A. Mallat,et al. Association of the Cannabinoid Receptor 2 (CB2) Gln63Arg Polymorphism with Indices of Liver Damage in Obese Children: An Alternative Way to Highlight the CB2 Hepatoprotective Properties , 2011 .
[51] C. Sagnelli,et al. Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients , 2011, Hepatitis monthly.
[52] P. Bacchetti,et al. Influence of cannabis use on severity of hepatitis C disease. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[53] Qilong Yi,et al. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis , 2008, AIDS.
[54] J. Rodríguez-Orengo,et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. , 2006, Journal of hepatology.
[55] M. Koziel. Influence of HIV co-infection on hepatitis C immunopathogenesis. , 2006, Journal of hepatology.
[56] G. Cabral,et al. Effects on the immune system. , 2005, Handbook of experimental pharmacology.